Clinical trials: Generalized Pustular Psoriasis
Palmoplantar Pustulosis
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
- Trial name
- NCT05174065
- Testing
- Apremilast
- Where
- 40 sites in Japan
- Volunteers
- 176 people
- Sponsor
- Amgen
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis.
- Trial name
- NCT07000630
- Testing
- Deucravacitinib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University First Hospital
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Palmoplantar Pustulosis (PPP)
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of…
- Trial name
- NCT07503652
- Testing
- Xeligekimab Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Hospital of China Medical University
Psoriasis
Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
The purpose of this study was to assess efficacy and safety data of secukinumab in Japanese subjects with generalized pustular psoriasis (GPP).
- Trial name
- NCT01952015
- Testing
- Secukinumab
- Where
- 10 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Palmoplantar Pustulosis
Immune Signature of Palmoplantar Pustulosis
This study is being done to learn more about a less common "type" of psoriasis, called palmoplantar pustulosis (PPP). The majority of the current treatments used for this type of psoriasis have only a moderate effect on PPP.
- Trial name
- PPP (NCT01780857)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Palmoplantar Pustulosis
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
The purpose of this study is to describe the treatment patterns of participants receiving systemic treatment for of palmoplantar pustulosis (PPP) in Japan.
- Trial name
- ProPuP (NCT04459507)
- Testing
- No intervention
- Where
- 39 sites in Japan
- Volunteers
- 276 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT03988335
- Testing
- RIST4721
- Where
- 17 sites in Canada, Germany
- Volunteers
- 35 people
- Sponsor
- Aristea Therapeutics, Inc.
Palmoplantaris Pustulosis
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP.
- Trial name
- NCT04057937
- Testing
- Apremilast
- Where
- 22 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Amgen
Palmoplantar Pustulosis
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
- Trial name
- NCT05710185
- Testing
- Deucravacitinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Brigham and Women's Hospital
Palmoplantar Pustulosis (PPP)
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles.
- Trial name
- NCT04451720
- Testing
- Risankizumab
- Where
- 39 sites in Japan
- Volunteers
- 119 people
- Sponsor
- AbbVie
Psoriasis
Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
This is a phase I, open label, single group study that is being performed to assess the safety, tolerability, Pharmacokinetics (PK) , Pharmacogenomics (PGx) and efficacy of a single dose of spesolimab in adult patients with…
- Trial name
- NCT02978690
- Testing
- Spesolimab
- Where
- 6 sites in France, Japan and 4 more
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT04061252
- Testing
- KHK4827
- Where
- 2 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Palmoplantar Pustulosis
Picankibart in Palmoplantar Pustulosis
1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to…
- Trial name
- NCT07552454
- Testing
- Picankibart
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Generalized Pustular Psoriasis (GPP), Adalimumab
Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently…
- Conditions
- Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese
- Trial name
- NCT02533375
- Testing
- Adalimumab
- Volunteers
- 10 people
- Sponsor
- AbbVie
Palmoplantar Pustulosis (PPP)
Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally.
- Trial name
- NCT07530367
- Testing
- Tofacitinib, Imatinib
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Generalized Pustular Psoriasis
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study.
- Trial name
- NCT04399837
- Testing
- Spesolimab
- Where
- 72 sites in United States, Argentina and 21 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027).
- Trial name
- NCT03886246
- Testing
- Spesolimab
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 131 people
- Sponsor
- LEO Pharma